Early Colonization of Bifidobacteria and Proper Immune Development
==================================================================

Microbiota establishment in newborns involves the assembly of a novel microbial community, a process that is dependent on several factors, including the mother's physiology (age, metabolic state, lifestyle, or even the potential transfer of microorganisms from mother to child before birth), mode of delivery, genetic background, environmental factors, type of feeding and early antibiotic use, among others ([@B35]). Similar results were found for preterm neonates, which are less abundantly colonized by bifidobacteria ([@B6]). Infant feeding is also a critical factor for bifidobacterial establishment in the gut, and breast-fed infants have been shown to possess higher levels of bifidobacteria than formula-fed infants ([@B103]); these high bifidobacterial levels decrease after breast milk cessation ([@B12]).

Pioneering studies revealed reduced levels of bifidobacteria in the gut microbiota composition of infants at high risk of atopic disease at 3 weeks and 3 months of age, and a higher incidence of atopic disease was found in this group of infants by the age of 1 year ([@B42]). Similarly, lower bifidobacterial levels were found in 3-month-old infants who later developed atopy at 2 years of age, or asthma at 4 years of age ([@B20]). All these data point to a critical role for bifidobacteria in the maturation of our immune system from gestation to childhood, suggesting that the low abundance of these early colonizers is associated with a deviated physiological state in infancy. Indeed, current evidence suggests a role of early life bifidobacteria establishment in programming future health. Therefore, it is of great importance to know the specific strains (and species) able to regulate immune responses, either directly or indirectly through the modulation of the gut microbiota, and the underlying mechanisms, in order to design dietary strategies focused on preventing immune-related disorders.

Strain-Specific Immunomodulatory Activities/*In Vitro* and *In Vivo* Models of Study
====================================================================================

*In Vitro* Models
-----------------

*In vitro* models have important limitations but they enable the preliminary screening of the effects that bacterial cells or fractions might have on different components of the immune response ([@B47]). Most *in vitro* models based on immune cells employ peripheral blood mononuclear cells (PBMCs). In this way, whole cells of *B. longum*, *B. breve*, *B. bifidum*, and *B. animalis* subsp. *lactis* strains demonstrated capacity to induce dendritic cell (DC) maturation, and a species/strain-dependent T cell polarization response ([@B56]; [@B52]; [@B65]). These studies revealed that, while *B. animalis* and many *B. longum* strains induced the production of the modulatory cytokine IL10 to varying degrees, the greatest strain-dependent differences were displayed in TNFα and INFγ production (**Figure [1](#F1){ref-type="fig"}**). Stimulation of PBMCs with subcellular fractions of bifidobacteria, including cytoplasmic, surface extracts, and supernatants, has also allowed the identification of molecular determinants of the elicited effects. For instance, a trypsin-labile cytoplasmic fraction of a *B. bifidum* strain was identified as the effector of CD8^+^ T cell activation; and supernatants of *B. breve* BB99 and *B. longum* 1941 exerted a regulatory T cell induction ([@B63]). PBMC models are thus useful to identify desirable immune profiles in probiotic strain screenings ([@B51]).

![Schematic representation of the effects on immune functions that certain strains of *B. animalis*, *B. longum* **(Left)**, and *B. bifidum* **(Right)** have demonstrated in *in vitro* and *in vivo* experiments. Many *B. animalis* and *B. longum* strains have demonstrated capacity to promote a Th1 response, while, on the contrary, some *B. bifidum* strains have been revealed capable to induce a Th17 polarization. Treg responses can also be regulated by certain strains of other species. Immunomodulatory properties are strain-dependent, and further evidence is needed in order to give to each bifidobacteria species a specific immune response in the intestinal mucosa.](fmicb-08-02345-g001){#F1}

Other *in vitro* models differentiate DCs, a specialized type of antigen presenting cells, from monocytes. DCs are regarded as the main guardians of the intestinal mucosa and are important in initiating the microbiota--immune system cross-talk. Their pattern recognition receptors (PRRs) interact with specific microbial-associated molecular patterns (MAMPs), which orchestrated molecular cascades that will determine the nature of the immune response ([@B37]; [@B100]). *In vitro* differentiated DCs allowed the identification of specific domains of a *B. bifidum* surface protein and the exopolysaccharide (EPS) of *B. longum* 35624, as the effectors of the immune responses elicited by the strains ([@B24]; [@B78]). DC models have also been used to predict the anti-inflammatory potential of bifidobacterial strains/molecules in specific population groups; for instance, bifidobacteria improved antigen uptake and processing by DC from Crohn's disease patients ([@B85]).

Other *in vitro* models using immune cells employ murine splenocytes ([@B91]; [@B84]), macrophage-like cell lines ([@B26]; [@B49]; [@B62]), or cells isolated from the gut-associated lymphoid tissues (GALT) ([@B34]), although they have not been widely used to examine the immunomodulation potential of bifidobacteria and thus their utility to predict immune responses is yet to be confirmed.

The immunomodulation potential of bifidobacteria has also been studied on enterocytes including Caco-2 or HT29 cell models ([@B8]; [@B11]; [@B44]; [@B5]; [@B77]; [@B53]). Although the immune response of epithelial cells is much more limited than the one exerted by specialized immune cells, enterocytes are more directly exposed to the intestinal milieu and are considered to play a key role in initiating the bifidobacteria--host interactions.

Beyond that, co-culture systems employing both immune and intestinal cells have also been implemented to study microbial--host interactions and promise to overcome some of the limitations of single cell type models ([@B14]). However, few studies have used them on bifidobacteria ([@B71]). The application of organized multicellular systems like intestinal organoids for these kinds of studies is envisaged ([@B66]).

*In Vivo* Models
----------------

Germ-free (GF) and conventional *in vivo* models, including healthy and disease-induced models, have shed light on the immune modulation capability of bifidobacterial strains including live and heat-killed cells ([@B86]). Screening of a large collection of gut symbionts on GF mice identified a *B. adolescentis* strain which induces a robust Th17 response, albeit not inducing intestinal inflammation ([@B90]). However, immune responses may vary strongly depending on the health status of the host, as the human sera of *Clostridium difficile* patients were shown to be more reactive against *B. longum* extracts than that of healthy individuals ([@B22]).

*In vivo* models of intestinal diseases have demonstrated the potential of *B. bifidum* and *B. animalis* strains to restore immune markers and intestinal barrier in low chronic inflammation models ([@B69]). Similarly, *B. longum* CECT 7347 attenuated the production of inflammatory cytokines and the CD4^+^ T cell-mediated immune response in a gliadin-induced enteropathy model ([@B48]). Other disease models, described below, have been tested in literature. In food-allergy models, a vesicle-derived protein from *B. longum* ([@B45]) and a *B. animalis* ([@B17]) strain, administered during lactation, exerted immunomodulatory effects. In a gut model, *B. longum* strain 51-A reduced inflammation ([@B98]). Finally, in obesity models, *B. pseudocatenulatum* restored the lymphocyte--macrophage balance and *B. adolescentis* IM38 improved high-fat-diet induced colitis inhibiting NF-κB activation ([@B64]; [@B50]). Furthermore, the role of bifidobacteria in responsiveness to immunotherapy has recently been suggested. Accordingly, using tumor models in mice, *Bifidobacterium* administration was shown to improve tumor-specific immunity and response to therapy through augmented DC function, opening new avenues to exploit the bifidobacterial-immune dialog in the context of this disease ([@B81]).

Finally, non-murine *in vivo* models, like pig models, are very attractive for the study of microbe--host interactions due to the similarities in the gastrointestinal function and development between pigs and humans. In this context, bifidobacterial administration in neonatal piglets has been shown to increase the production of intestinal IL-10 ([@B27]), and to improve B and T cell responses following rotavirus vaccination ([@B99]; [@B43]; [@B39]). In addition, colonization with a combination of lactobacilli and bifidobacteria in non-vaccinated gnotobiotic piglets reduced the severity of rotavirus infection, while in vaccinated animals enhanced Th1 ([@B10]). Thus, *in vivo* models closer to humans are valuable to study the immunomodulatory potential of certain strains, should be "particularly in the context of pig models in order to study pre-term birth and necrotizing enterocolitis (NEC)" ([@B68]).

Humans
------

Different immunoreactive proteins from two *B. longum* strains have been identified in mono-colonized mice, rabbit, and human sera, revealing that the effects are strain and host specific ([@B22]) and emphasizing the need to further support *in vitro* immunomodulatory effects in clinical trials. A summary of human studies that focus on the immunomodulatory effects of bifidobacterial consumption in multiple disorders, in some of which gut microbial ecology dysbiosis and altered immune profiles coexist, is presented in **Table [1](#T1){ref-type="table"}**.

###### 

*Bifidobacterium* role on diseases with an immunological component.

  Species/strains tested                                            Population                                                                                                            Observations                                                                                                                                                                          Reference
  ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  **Intervention studies**                                                                                                                                                                                                                                                                                                                                                      
  *B. lactis* BB12                                                  Healthy adults                                                                                                        Four weeks administration of yogurt with the strain resulted in lower expression of TLR-2 on CD14^+^HLA-DR^+^ cells and reduction in TNF-α secretion                                  [@B58]
  *B. lactis* Bi-07                                                 Healthy elderly adults                                                                                                Four weeks administration improved phagocytic activity of monocytes and granulocytes                                                                                                  [@B54]
  *B. animalis* ssp. *lactis* HN019                                 Systematic meta-analysis on four clinical trials/healthy elderly subjects                                             The strain supplementation resulted in increased PMN phagocytic capacity and moderately increased NK cell tumoricidal activity                                                        [@B60]
  *B. animalis* LKM512                                              Atopic dermatitis adult patients                                                                                      Administration into a yogurt daily for 4 weeks induced a Th1-type cytokine profile                                                                                                    [@B55]
  *B. lactis* NCC2818                                               Seasonal allergic rhinitis to grass pollen/adults                                                                     Eight weeks probiotic administration reduced Th2-cytokines secretion and CD63 expressing basophiles correlating to improved symptoms                                                  [@B80]
  *B. lactis* HN019                                                 Metabolic syndrome patients                                                                                           Decrease in TNFα and IL6 correlated to improvement in cardiovascular risk markers                                                                                                     [@B9]
  *B. breve* BR03 and *B. breve* B632                               Cystic fibrosis/children                                                                                              Three months administration of the two strains combination reduced proinflammatory markers                                                                                            [@B46]
  *Lb. gasseri KS-13*, *B. bifidum G9-1*, and *B. longum MM-2*      Healthy elderly population                                                                                            Three weeks administration of probiotic mix maintained CD4+ lymphocytes and resulted in a more anti-inflammatory cytokines profile with increased IL-10                               [@B83]
  *B. breve* M-16V and *B. longum* BB536                            Prenatal administration to pregnant mothers 1 month prior delivery and to the infants during 6 months                 Reduced risk of developing eczema in the probiotic group                                                                                                                              [@B15]
  *B. longum* BB536, *B. infantis* M-63, *B. breve* M-16V mixture   Seasonal allergic rhinitis and intermittent asthma/children                                                           Improvement of symptoms following 4 weeks of probiotic administration                                                                                                                 [@B61]
  *B. longum* BB536                                                 Healthy newborns                                                                                                      The number of IFN-γ secretion cells and the ratio of IFN-γ/IL-4 secretion cells was increased, suggesting improvement of Th1 function                                                 [@B101]
  *B. longum* BB536                                                 Elderly subjects receiving enteral tube feeding                                                                       Twelve weeks administration resulted in increased serum IgA and maintenance of NC cell activity                                                                                       [@B2]
  *B. longum* 35624                                                 Patients of ulcerative colitis (UC), chronic fatigue syndrome (CFS), and psoriasis, as compared to healthy controls   Six to eight weeks of probiotic administration reduced CRP, TNFα, and IL6 in UC, CFS, and psoriasis patients                                                                          [@B23]
  *B. infantis* NLS                                                 Celiac adults                                                                                                         Six weeks probiotic administration reduced Paneth cells numbers and expression of α-defensine-5, as compared to patients under a gluten-free diet without probiotic supplementation   [@B70]
  *B. longum* CECT 7347                                             Children with newly diagnosed coeliac disease                                                                         Three months administration resulted in reduced peripheral CD3+ lymphocytes, TNFα, and sIgA in stools                                                                                 [@B67]
  **Observational studies**                                                                                                                                                                                                                                                                                                                                                     
  *B. breve*                                                        Eczema risk in children at high risk of allergic disease                                                              Early *B. breve* colonization was associated to reduced risk of eczema                                                                                                                [@B40]
  *Bifidobacterium* spp. and *B. adolescentis*                      Allergic asthma in adults                                                                                             Reduction in gut bifidobacterial representation and *B. adolescentis* prevalence within the bifidobacterial group in the studied population                                           [@B29]
  *B. pseudocatenulatum*                                            Gout patients                                                                                                         *B. pseudocatenulatum* depletion in gout patients                                                                                                                                     [@B25]

Summary of observational and intervention studies in humans

.

Molecular Structures Driving Specific Immunomodulatory Effects
==============================================================

Findings from the last 10 years support the idea that bifidobacteria exert their beneficial effects on host health through the immunomodulatory action of some of their surface-associated molecules ([@B36]; [@B16]). This is based on the interaction of a specific bifidobacteria molecule, a MAMP, with a PRR presents on the membrane of epithelial/immune cells, which mostly configures the cellular structure of the intestinal mucosa ([@B87]). Although mucosa itself is differently organized, depending on the gut section considered, bifidobacteria are thought to exert their immunomodulatory activity mainly in the colon and in the distal part of the ileum, where up to 46% of the Peyer's patches are located ([@B97]). Scientific evidence has shown the presence of immunomodulatory compounds in bifidobacteria spent medium which are released during bacterial growth (**Figure [1](#F1){ref-type="fig"}**).

Proteins and Peptides
---------------------

Bifidobacterial proteins are one of the targets of human immunoglobulins, notably IgA, which is secreted into the gut lumen in order to control the commensal microbiota populations. Up to six different extracellular proteins from the strains *B. longum* subsp. *longum* NCIMB 8809, *B. bifidum* LMG 11041^T^, and *B. animalis* subsp. *lactis* IPLA 4549 were recognized by pooled sera from healthy individuals, or Inflammatory Bowel Disease (IBD) patients ([@B28]). Perhaps the best known example of an immunomodulatory protein is the extracellular serpin secreted by *B. longum* subsp. *longum*. Serpin stands for [ser]{.ul}ine [p]{.ul}rotease [in]{.ul}hibitor and includes different families that share the ability to bind and irreversibly inactivate proteases. The gene coding for serpin is not widely distributed among the genus *Bifidobacterium*, being present in up to nine species so far ([@B93]). More precisely, the targets of serpin secreted by *B. longum* are two important pro-inflammatory proteases: human neutrophil and pancreatic elastases ([@B41]), proteases that have been shown to induce the serpin gene through a two-component regulatory system ([@B4]). Limiting the local action of these proteases suggests a role of bifidobacteria in the maintenance of gut homeostasis.

Other well-known protein structures with an immunomodulatory action are pili, which self-assemble on the bifidobacteria surface in the form of filaments and have a primary function of adherence to the intestinal surface ([@B96]). Lower levels of IL10 and higher levels of TNFα were detected in the murine cecum mucosa as a response to the presence of a *Lactococcus lactis* strain, genetically modified for producing *B. bifidum* pili. This response was not observed in the wild-type strain, suggesting a specific interaction of these structures with the gastrointestinal mucosa ([@B95]). Another protein with an immunomodulatory effect is the peptidoglycan hydrolase TgaA, a surface-associated protein in *B. bifidum*, which was shown to induce IL2 production in monocyte-derived dendritic cell (MoDC), the key cytokine in T~reg~ cell expansion ([@B104]; [@B24]). Finally, our own work has revealed the presence of immunomodulatory peptides encrypted in the sequences of bifidobacteria proteins. In this sense, a peptide contained within the sequence of the protein translocase subunit SecA of *B. longum* DJ010A triggered a marked Th17 response when incubated with human PBMCs ([@B32]).

EPSs
----

EPSs are carbohydrate polymers that are synthesized and exhibited in the bifidobacterial surface ([@B34]). Although the exact molecular mechanisms have not been described so far, EPSs have a great impact on the host immune function ([@B30]). In a murine model, the EPS-producing strain *B. breve* UCC2003 was associated with increases in the mucosal levels of the pro-inflammatory IL12, INFγ, and TNFα which turned out to protect against *Citrobacter* infection ([@B18]). Murine J77A.1 macrophages challenged with the EPS produced by strain *B. longum* BCRC 14634 increased the production of the anti-inflammatory cytokine IL10 when compared to basal conditions, and when challenged with lipopolysaccharide, the presence of the EPS was linked to lower levels of the pro-inflammatory cytokine TNFα ([@B102]). It is noteworthy that the rhamnose-rich, high-molecular weight EPS isolated from the strain *B. animalis* subsp. *lactis* IPLA-R1 was able to increase IL10 production in a PBMC model and to decrease the TNFα production in human colonic biopsies ([@B33]). Moreover, the administration of strain IPLA-R1 to Wistar rats was associated with higher serum levels of TGFβ and lower serum levels of the pro-inflammatory interleukin IL6 ([@B76]).

EPS produced by specific bifidobacteria strains have been shown as molecules able to prevent exacerbated pro-inflammatory responses. *B. longum* subsp. *longum* 35624 is a strain which has shown clinical efficacy in Irritable Bowel Syndrome, a human condition cursing with chronic mucosal inflammation ([@B3]). The anti-inflammatory effects elicited by this strain were shown to rely in its surface-associated EPS, which prevented expansion of the pro-inflammatory Th17 response compared to an exopolysaccharide-negative mutant derivative ([@B78]).

Finally, recent data on a mouse model of pathological cell shedding, EPS from *B. breve* UCC2003 appeared to confer protective effect through MyD88-dependent signaling ([@B38]). Diversity of gene clusters responsible for EPS biosynthesis is high among bifidobacterial species/strains (not to mention variations in the level of EPS production) and this diversity may hold tremendous potential for strain-specific immune responses.

DNA
---

Bifidobacteria possess genomes with high G+C proportions, and un-methylated CpG motifs derived from them can interact with the TLR 9 present on immune cells. Several publications have reported on the immunomodulatory activity of bifidobacterial DNA. CpG motifs have in one case been linked to a promotion of the T~h~1 response, dedicated to fight intracellular pathogens such as viruses ([@B57]). Another work described an oligodeoxynucleotide derived from the *B. longum* BB536 strain able to inhibit anti-ovalbumin--IgE titres in a murine model of type-I allergic response after ovalbumin injection ([@B89]).

Bifidobacterial Metabolism Triggers Cross-Feeding Mechanisms that Maintain Immune Homeostasis in the Gut
========================================================================================================

Many efforts are currently being pursued to understand the metabolic fluxes within the gut ecosystem among bifidobacteria, other members of the gut microbiota and the human host ([@B31]). A major metabolic contribution elicited by bifidobacteria from their host is represented by the breakdown of non-digestible, diet-derived glycans, and carbohydrates provided by the host known as host-derived glycans \[mucins and human milk oligosaccharides (HMOs)\] ([@B59]). Mucin is a host-produced glycan that constitutes one of the main barriers covering the gastrointestinal mucosa ([@B88]). Among bifidobacteria, only members of *B. bifidum* species have been shown to efficiently metabolize mucin ([@B73]; [@B92]; [@B75]). HMOs are present in high concentrations in human colostrum and breast milk. Bifidobacteria, which dominate during early life, are among the best described gut bacteria with the ability to utilize HMOs. Several species possess glycosyl hydrolases that cleave specific linkages within the HMO molecules, the best characterized being those synthesized by *B. bifidum* ([@B74]). HMOs are preferentially fermented by *B. bifidum* and *B. longum* species which, together with *B. breve*, are the most abundant in breast-fed infant gut microbiota ([@B79]). Thus, the ability of these species to utilize these otherwise indigestible carbohydrates explains their abundance in breast-fed neonates ([@B105]).

Metabolic cross-feeding mechanisms in the gut are commonly exploited by primary microbial degraders like bifidobacteria which, thanks to partial extracellular hydrolysis of specific complex carbohydrates (e.g., host-produced glycans), provide monosaccharides, oligosaccharides, or metabolites for other microbial gut inhabitants ([@B13]). As an example, *B. bifidum* PRL2010 is a strain specialized in the extracellular breakdown of host-glycans and, thus, in the release of simple sugars that can be utilized by other members of the (bifido)bacterial community ([@B94]). The subsequent fermentative metabolism of these carbohydrates generates end-metabolites, such as acetate and lactate, which are the main end-products of the bifidobacteria catabolism. Acetate released in the gut by bifidobacteria is used as substrates for other microbial gut fermenters, mainly butyrate and propionate producers ([@B19]). The production of these two major short-chain fatty acid metabolites have been shown to have anti-inflammatory effects, and promotes and regulates the pool of colonic T~reg~ cells ([@B7]; [@B82]). By inhibiting histone deacetylase activity in DC and T cells, butyrate acts in the differentiation of T~reg~ cells, increasing the expression of the T~reg~ marker FoxP3 ([@B21]). Signalization has been proposed to be mediated by the butyrate receptors in epithelial and immune cells named FFAR3 (free fatty acid receptor 3) and GPR109A ([@B1]; [@B72]).

Concluding Remarks
==================

Bifidobacterial cells, their subcellular fractions, or specific molecules produced by these microorganisms, hold an important potential to trigger immunomodulatory responses involved in the maintenance of our healthy physiological state. However, these responses are poorly understood and need for more research on how this molecular communication between bifidobacteria and host cells is performed. Additionally, the increasing knowledge on the role played by different gut microbiota members, and the understanding of the cross-talk and cross-feeding interaction processes between bifidobacteria, the host, and the surrounding network of intestinal microbes, should facilitate the synergistic use of different intestinal microorganisms to modulate the immunological and inflammatory processes in a microbial dependent way.
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